YYSW001 JAK1 Inhibitor Preclinical Pharmacology and Efficacy Data

Comprising preclinical data for the JAK1 inhibitor compound YYSW001, including its IC50 of 6 nM and >50-fold selectivity over JAK2. It reports 61.8% oral bioavailability and efficacy results from rat collagen-induced and adjuvant-induced arthritis models. The dataset is 5.3 KB in size, but the row and column counts are unknown.

Use Cases

• Compare JAK1 inhibition IC50 values and JAK2 selectivity ratios across different compound series for structure-activity relationship analysis.
• Analyze the correlation between oral bioavailability percentage and therapeutic efficacy in preclinical arthritis models.
• Benchmark the hematologic dysfunction and weight loss liabilities of YYSW001 against upadacitinib using data from rat models.

Strengths

• Includes specific, quantitative pharmacology metrics such as a JAK1 IC50 of 6 nM and >50-fold selectivity over JAK2.
• Reports concrete efficacy outcomes from two established preclinical arthritis models: rat collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA).
• Provides a key pharmacokinetic parameter with 61.8% oral bioavailability.

Limitations

• The dataset is very small at 5.3 KB, indicating limited scope and likely a summary of key results rather than raw experimental data.
• The structure is unknown, with no column names or sample data provided, complicating direct analysis.
• Data is derived from preclinical animal models, which may not directly translate to human clinical outcomes.

Provenance

Source

figshare, authored by Kaiyong Hu.

Collection Method

Data originates from the preclinical pharmacological evaluation and efficacy studies described in the associated publication.

Freshness

Last updated on 2026-03-20.